The U.S. Food and Drug Administration has granted accelerated approval for Novo Nordisk’s GLP-1 agonist Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), a prevalent form of fatty liver disease. This approval marks Wegovy as the first GLP-1 drug authorized for this indication, based on Phase 3 data demonstrating improvements in liver scarring and resolution of MASH without scarring progression. Novo Nordisk’s move positions Wegovy to compete directly with Madrigal Pharmaceuticals’ Rezdiffra, the only other approved MASH therapy, which has posted strong sales since its 2024 launch. Analysts anticipate Wegovy’s multi-billion-dollar obesity market success could disrupt the evolving MASH treatment landscape, though patient subpopulations may differentiate drug uptake.